Epic Sciences

In the News


Video - Genomic Sequencing: Precision data to better fight advanced cancer

Portland, KATU2 — Patient Bryce Olson shows the importance of personalized medicine, including the Oncotype DX® AR-V7 Nucleus Detect™ test, in aiding pivotal metastatic castration-resistant prostate cancer treatment decisions. The test, developed by Epic Sciences and commercially available by Genomic Health, is now covered by Medicare.


Video - PROPHECY Trial: Circulating Tumor Cell as a Biomarker in mCRPC - Andrew Armstrong

San Diego, UroToday — Charles Ryan and Andrew Armstrong discuss the PROPHECY study, a PCF challenge award, co-funded by Movember. Seeing the future with predictive biomarkers was the foundational vision for this study. For men with castration-resistant prostate cancer undergoing a range of therapies, two AR-V7 tests were prospectively compared to see how well they predicted both progression-free survival and overall survival.


Video - New test extending lives of advanced prostate cancer patients

Bryce Olson discusses the Oncotype DX® AR-V7 Nucleus Detect™ test, developed by Epic Sciences and commercially available through Genomic Health, with ABC 10 News. The test determines which men with late-stage metastatic prostate cancer will benefit from AR-targeted therapy or chemotherapy.


Blood Test May Identify Cancer Patients Who Respond to PSMA-Targeted Therapies

San Diego, CLP Magazine — In a study sponsored by Epic Sciences, San Diego, in partnership with Memorial Sloan Kettering Cancer Center, researchers have demonstrated that a liquid biopsy blood test may be used before treatment is initiated in clinical trials to find patients who are likely to benefit from therapies targeting prostate-specific membrane antigen.


Metastatic Breast Cancer Clinical Trial Forged by Epic Sciences, Canadian Consortium

New York, GenomeWeb – Epic Sciences announced today that it has partnered with four major Canadian breast cancer centers on a clinical trial to see if the firm's blood test can be used to predict the risk of late recurrence of metastatic breast cancer in female patients.


Epic Sciences, Genomic Health Get Medicare LCD for Prostate Cancer Diagnostic

San Diego, Clinical OMICs – Epic Sciences and Genomic Health announced that Medicare Administrative Contractor Palmetto GBA, has issued a positive final local coverage determination (LCD) for the Oncotype DX AR-V7 Nucleus Detect test. The final LCD recommends Medicare coverage effective December 10, 2018.


Epic Sciences Continues Research on Multiple Fronts; Remains Quiet on Dx Development Pipeline

New York, GenomeWeb – With its first commercial diagnostic now fully launched and awaiting a final coverage decision by Medicare, Epic Sciences is keeping quiet about concrete plans for a pipeline of additional clinical assays, though it continues to collect data from research studies which may provide possibilities for future translation.